Qualigen Therapeutics (QLGN) announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock, effective at 12:01 a.m. Eastern time on November 5, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol “QLGN.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QLGN:
- Qualigen Therapeutics files to sell 14M shares of common stock
- Qualigen Therapeutics Board Experiences Key Changes
- Qualigen Therapeutics Announces Executive Shakeup and Board Revamp
- Qualigen Therapeutics appoints Kevin Richardson as Interim CEO and CFO
- Qualigen Therapeutics Granted Nasdaq Listing Extension